Movers and SHAKERS
Onconova Therapeutics Inc. (ONTX)
CDK4/6 Program Advances into Clinic in China
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Trial initiation in China by research partner Hanx. Onconova announced the commencement of trial of its CDK4/6 and ARK5 inhibitor ON 123300 in China by its partner, HanX Biopharmaceuticals. Hanx and Onconova established the research collaboration in 2017.
What else is there for Onvonova? The company anticipates filing for the investigational new drug (IND) application to evaluate ON 123300 in the United States in Q4 2020 for this program. We believe this will be...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.